Matthew P Deek1, Brian Benenati1, Sinae Kim2, Ting Chen1, Inaya Ahmed1, Wei Zou1, Joseph Aisner3, Salma K Jabbour4. 1. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. 2. Department of Biostatistics, School of Public Health, Rutgers University, Piscataway, New Jersey; Biometrics Division, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. 3. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. 4. Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. Electronic address: jabbousk@cinj.rutgers.edu.
Abstract
PURPOSE: To determine the relationships between radiation doses to the thoracic bone marrow and declines in blood cell counts in non-small cell lung cancer (NSCLC) patients treated with chemoradiation therapy (CRT). METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. Dose-volume histogram (DVH) parameters for the thoracic vertebrae (TV), sternum, scapulae, clavicles, and ribs were assessed for associations with changes in blood counts during the course of CRT. Linear and logistic regression analyses were performed to identify associations between hematologic nadirs and DVH parameters. A DVH parameter of Vx was the percentage of the total organ volume exceeding x radiation dose. RESULTS: Grade ≥ 3 hematologic toxicity including neutropenia developed in 21% (n=11), leukopenia in 42% (n=22), anemia in 6% (n=3), and throbocytopenia in 2% (n=1) of patients. Greater RT dose to the TV was associated with higher risk of grade ≥ 3 leukopenia across multiple DVH parameters, including TV V20 (TVV) (odds ratio [OR] 1.06; P=.025), TVV30 (OR 1.07; P=.013), and mean vertebral dose (MVD) (OR 1.13; P=.026). On multiple regression analysis, TVV30 (β = -0.004; P=.018) and TVV20 (β = -0.003; P=.048) were associated with white blood cell nadir. Additional bone marrow sites (scapulae, clavicles, and ribs) did not affect hematologic toxicity. A 20% chance of grade ≥ 3 leukopenia was associated with a MVD of 13.5 Gy and a TTV30 of 28%. Cutoff values to avoid grade ≥ 3 leukopenia were MVD ≤ 23.9 Gy, TVV20 ≤ 56.0%, and TVV30 ≤ 52.1%. CONCLUSIONS: Hematologic toxicity is associated with greater RT doses to the TV during CRT for NSCLC. Sparing of the TV using advanced radiation techniques may improve tolerance of CRT and result in improved tolerance of concurrent chemotherapy.
PURPOSE: To determine the relationships between radiation doses to the thoracic bone marrow and declines in blood cell counts in non-small cell lung cancer (NSCLC) patients treated with chemoradiation therapy (CRT). METHODS AND MATERIALS: We included 52 patients with NSCLC treated with definitive concurrent carboplatin-paclitaxel and RT. Dose-volume histogram (DVH) parameters for the thoracic vertebrae (TV), sternum, scapulae, clavicles, and ribs were assessed for associations with changes in blood counts during the course of CRT. Linear and logistic regression analyses were performed to identify associations between hematologic nadirs and DVH parameters. A DVH parameter of Vx was the percentage of the total organ volume exceeding x radiation dose. RESULTS: Grade ≥ 3 hematologic toxicity including neutropenia developed in 21% (n=11), leukopenia in 42% (n=22), anemia in 6% (n=3), and throbocytopenia in 2% (n=1) of patients. Greater RT dose to the TV was associated with higher risk of grade ≥ 3 leukopenia across multiple DVH parameters, including TV V20 (TVV) (odds ratio [OR] 1.06; P=.025), TVV30 (OR 1.07; P=.013), and mean vertebral dose (MVD) (OR 1.13; P=.026). On multiple regression analysis, TVV30 (β = -0.004; P=.018) and TVV20 (β = -0.003; P=.048) were associated with white blood cell nadir. Additional bone marrow sites (scapulae, clavicles, and ribs) did not affect hematologic toxicity. A 20% chance of grade ≥ 3 leukopenia was associated with a MVD of 13.5 Gy and a TTV30 of 28%. Cutoff values to avoid grade ≥ 3 leukopenia were MVD ≤ 23.9 Gy, TVV20 ≤ 56.0%, and TVV30 ≤ 52.1%. CONCLUSIONS:Hematologic toxicity is associated with greater RT doses to the TV during CRT for NSCLC. Sparing of the TV using advanced radiation techniques may improve tolerance of CRT and result in improved tolerance of concurrent chemotherapy.
Authors: R Charles Nichols; Soon N Huh; Randal H Henderson; Nancy P Mendenhall; Stella Flampouri; Zuofeng Li; Harry J D'Agostino; J Davis Cury; Dat C Pham; Bradford S Hoppe Journal: Clin Lung Cancer Date: 2011-04-27 Impact factor: 4.785
Authors: Chandra P Belani; Hak Choy; Phil Bonomi; Charles Scott; Patrick Travis; John Haluschak; Walter J Curran Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Vivien W Chen; Bernardo A Ruiz; Mei-Chin Hsieh; Xiao-Cheng Wu; Lynn A G Ries; Denise R Lewis Journal: Cancer Date: 2014-12-01 Impact factor: 6.860
Authors: Sarah M McGuire; Yusuf Menda; Laura L Boles Ponto; Brandie Gross; John Buatti; John E Bayouth Journal: Int J Radiat Oncol Biol Phys Date: 2011-02-06 Impact factor: 7.038
Authors: M Poudenx; P Y Bondiau; E Chamorey; N Venissac; J Otto; N Pourel; O Castelnau; E Tessier; B De Surmont Salasc; J F Berdah; D Pop; C Michel; J Mouroux Journal: Oncology Date: 2012-09-13 Impact factor: 2.935
Authors: Matthew P Deek; Sinae Kim; Inaya Ahmed; Bruno S Fang; Wei Zou; Jyoti Malhotra; Joseph Aisner; Salma K Jabbour Journal: Am J Clin Oncol Date: 2018-04 Impact factor: 2.339
Authors: Emily R Domínguez; Jennifer Orona; Kevin Lin; Carlos J Pérez; Fernando Benavides; Donna F Kusewitt; David G Johnson Journal: Cell Cycle Date: 2017-06-08 Impact factor: 4.534
Authors: Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: J Gastrointest Oncol Date: 2022-02
Authors: Christian L Barney; Nicholas Scoville; Eric Allan; Ahmet Ayan; Dominic DiCostanzo; Karl E Haglund; John Grecula; Terence Williams; Meng Xu-Welliver; Gregory A Otterson; Jose G Bazan Journal: Int J Radiat Oncol Biol Phys Date: 2017-11-23 Impact factor: 7.038
Authors: Andrew Zhang; Matthew P Deek; Sinae Kim; Mutlay Sayan; Alison Grann; Raquel T Wagman; Usha Malhotra; Lara Hathout; Nrusingh Biswal; Yin Zhang; John Langenfeld; Timothy Kennedy; David A August; Salma K Jabbour Journal: J Gastrointest Oncol Date: 2019-06